Injectafer denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Injectafer on Medical-Necessity Grounds

Injectafer (ferric carboxymaltose) is an intravenous iron replacement therapy. UnitedHealthcare's medical-necessity denials for Injectafer typically assert that the clinical record does not sufficiently demonstrate that oral iron is inadequate or contraindicated, or that the severity of iron deficiency anemia has not been documented to the plan's standard. Because IV iron carries a higher cost than oral therapy, insurers scrutinize whether the transition from oral to intravenous treatment is justified.

## Why This Denial Is Appealable

Medical-necessity determinations are reviewable. If your prescribing clinician has documented a clinical reason — such as intolerance, malabsorption, an underlying condition affecting oral iron uptake, or a setting requiring rapid repletion — that reason must be evaluated on its merits. A denial that ignores documented clinical findings is subject to challenge under both internal and external appeal rights.

## Your Federal Appeal Rights

• Internal appeal: Submit a written appeal to UHC within the timeframe stated on your Explanation of Benefits (EOB). UHC must respond within the regulatory deadline.
• External review (ACA §2719): If you exhaust the internal process or receive an adverse determination, you have the right to request independent external review. The external reviewer is a board-certified clinician with no financial relationship to UHC.
• ERISA §503 (employer plans): If your plan is employer-sponsored and self-funded, ERISA's full-and-fair review provisions apply. You are entitled to the complete claims file and all clinical criteria used.
• Expedited review: If your condition is urgent, request expedited internal and external review simultaneously.
• Timeline: External review requests must generally be filed within four months of the final internal denial. Do not let this window lapse.

## Documentation to Gather

1. Diagnosis confirmation: Labs, clinical notes, and any imaging or endoscopy that establishes the underlying cause of iron deficiency. 2. Oral iron trial history: Dates, formulations tried, doses, duration, and documented outcomes (inadequate response, intolerance, adverse effects). 3. Clinical severity: Chart notes reflecting symptom burden, functional impact, and any comorbidities that affect iron management. 4. Prescriber medical-necessity letter: A detailed letter from your treating clinician explaining why Injectafer is the appropriate therapy for your specific situation, referencing the applicable guideline organization's recommendations (e.g., the relevant hematology or gastroenterology society guidelines). 5. UHC's coverage policy: Download UHC's current published clinical policy for IV iron. Read each stated criterion exactly.

## Criteria-Mapping Structure

Create a two-column table. In the left column, copy each requirement verbatim from UHC's published policy and from the FDA-approved Injectafer prescribing information. In the right column, cite the exact chart entry — date, clinician, finding — that satisfies each requirement. If a criterion is met, state how. If a criterion is inapplicable, explain why. Submit this mapping with your appeal letter. This structure forces the reviewer to address each point individually and is far more effective than a narrative alone.